Kliničke studije za Lupus u državi Illinois
14 studija za Lupus traži sudionike na lokacijama u državi Illinois.
Gradovi u državi Illinois
Službeni tekst studije (engleski)
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Sl0044 50699, Chicago
- Sl0044 50717, Willowbrook
U tijeku regrutacijaFaza 3
Od 16 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT06617325Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
- Willow Rheumatology Wellness, Willowbrook
U tijeku regrutacijaFaza 3
Od 12 do 100 godina · Oba spola · Ažurirano 1. lis 2026. · NCT06133972An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
- Research Site, Chicago
- Research Site, Chicago
U tijeku regrutacijaFaza 3
Od 5 do 17 godina · Oba spola · Ažurirano 30. ruj 2026. · NCT05835310A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- Research Site, Willowbrook
U tijeku regrutacijaFaza 3
Od 18 do 70 godina · Oba spola · Ažurirano 25. ruj 2026. · NCT07430306A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
- Willow Rheumatology and Wellness PLLC, Willowbrook
U tijeku regrutacijaFaza 3
Od 18 do 75 godina · Oba spola · Ažurirano 25. ruj 2026. · NCT07438496A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
- Advanced Quality Medical Research /ID# 279147, Orland Park
U tijeku regrutacijaFaza 1
Od 18 do 75 godina · Oba spola · Ažurirano 25. ruj 2026. · NCT07607964A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
- University of Chicago, Chicago
U tijeku regrutacijaFaza 2
Od 16 do 70 godina · Oba spola · Ažurirano 17. ruj 2026. · NCT07328581A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
- Research Site, Chicago
U tijeku regrutacijaFaza 1/2
Od 18 do 70 godina · Oba spola · Ažurirano 10. ruj 2026. · NCT06897930A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- The University of Chicago Medical Center, Chicago
U tijeku regrutacijaFaza 1
Od 18 do 74 godina · Oba spola · Ažurirano 10. ruj 2026. · NCT07085104A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- Willow Rheumatology & Wellness, Willowbrook
U tijeku regrutacijaOpažajna studija
Od 16 godina i više · Oba spola · Ažurirano 3. ruj 2026. · NCT07175285A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago
U tijeku regrutacijaFaza 1
Od 18 do 70 godina · Oba spola · Ažurirano 28. kol 2026. · NCT06925542RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
U tijeku regrutacijaFaza 1/2
Od 18 do 65 godina · Oba spola · Ažurirano 26. kol 2026. · NCT06121297A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
- Advanced Quality Medical Research /ID# 278462, Orland Park
U tijeku regrutacijaFaza 1
Od 18 do 75 godina · Oba spola · Ažurirano 10. kol 2026. · NCT06977724Lupus Landmark Study: A Prospective Registry and Biorepository
- University of Chicago, Chicago
U tijeku regrutacijaOpažajna studija
Od 18 do 110 godina · Oba spola · Ažurirano 15. tra 2026. · NCT05934149Iz ClinicalTrials.gov, podaci preuzeti 4. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.